New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
17:04 EDTUTHR, SUPNSupernus receives $2M milestone payment for launch of Orenitram
Supernus Pharmaceuticals (SUPN) announced that United Therapeutics Corporation (UTHR) has paid Supernus a $2M milestone payment under United Therapeutics' license agreement with Supernus. This payment was due upon the launch of Orenitram Extended-Release Tablets for the treatment of pulmonary arterial hypertension, in the United States. Orenitram utilizes a Supernus patented technology platform. In addition to the launch milestone, Supernus will receive royalties on net sales of Orenitram, and may become entitled to additional milestone payments.
News For SUPN;UTHR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2015
06:09 EDTUTHRUnited Therapeutics agrees to sell PPRV to AbbVie for $350M
United Therapeutics (UTHR) announced that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher, or PPRV, to a subsidiary of AbbVie (ABBV). United Therapeutics received the PPRV when Unituxin was approved by the FDA for the treatment of neuroblastoma, a rare pediatric disease. Upon closing of the transaction, United Therapeutics will receive $350M in cash in exchange for the PPRV. The voucher was awarded by the FDA under a provision that encourages development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.
August 17, 2015
06:04 EDTUTHRUnited Therapeutics reports EC Marketing Authorisation for Unituxin
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use